FDA limits research of former AHA president for submitting false information

BMJ 2002; 325 doi: (Published 14 December 2002) Cite this as: BMJ 2002;325:1377
  1. Janice Hopkins Tanne
  1. New York

Just days before he completed his year as president of the American Heart Association on 30 June, Dr David Faxon signed a consent agreement with the Food and Drug Administration limiting his clinical research.

On 19 June 2002 Dr Faxon agreed that for three years he would not be the principal investigator for more than two FDA regulated clinical investigations at any one time, and that he would not be the principal clinical investigator for a study that enrolled more than 25 subjects. …

View Full Text

Log in

Log in through your institution


* For online subscription